We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
MSD’s Keytruda may become the first anti-PD-1 drug in Europe to be approved in combination with chemotherapy, following a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP).